therapeutic
-
US FDA clears investigational new drug application, phase 2B trial for Immuron’s NASH/Fatty liver therapeutic
Immuron announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission to commence a Phase 2b clinical trial of its bovine colostrum-derived therapeutic (IMM-124E) for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Fatty Liver.
therapeutic | 06 March 2012
-
VaxOnco to sponsor phase 1 trial of breast/ovarian cancer therapeutic vaccine
VaxOnco announced that following FDA IND approval, it will sponsor a phase 1 folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic. The …
therapeutic | 26 July 2011
-
Allergan to acquire dermatologic company, Vicept Therapeutics
Vicept Therapeutics and Allergan Inc announced that they have entered into a definitive agreement for Allergan to acquire all of the outstanding shares and assets of the privately-held dermatology company. The agreement, estimated to close in the thi…
therapeutic | 19 July 2011
-
AstraZeneca, PTC Therapeutics announce strategic oncology drug discovery collaboration
AstraZeneca and PTC Therapeutics Inc announced that they have entered into an exclusive research collaboration and license agreement. This is for the application of PTC’s proprietary GEMS technology (Gene Expression Modulation by Small-molecules) f…
therapeutic | 30 June 2011
-
Sanofi enters into research collaboration with Audion Therapeutics
Sanofi announced that it has entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative me…
therapeutic | 16 June 2011
-
Oceana Therapeutics announces strategic alliance with Dr Reddy in India
Oceana Therapeutics announced that it has entered into a multi-year exclusive agreement with Indian pharmaceutical giant Dr Reddy’s Laboratories Ltd giving rights to the sale and distribution of Deflux in India. Further terms of the transaction wer…
therapeutic | 17 May 2011
-
Durata Therapeutics announces worldwide rights for dalbavancin
Durata Therapeutics announced the company has attained worldwide rights for the development and commercialization of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin st…
therapeutic | 27 April 2011
-
Ascletis raises $100 million for specialty therapeutics venture
Ascletis Inc, a US-China specialty life sciences venture focused on cancer and infectious disease therapeutics, announced the company’s formation and completion of a Series A private equity financing. Ascletis has raised US$100 million in committed…
therapeutic | 07 April 2011
-
Pfizer launches global centers for therapeutic innovation
Pfizer established the global centers for therapeutic innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. The University o…
therapeutic | 11 March 2011
-
EpiTherapeutics, Abbott enter into oncology collaboration
EpiTherapeutics and Abbott are collaborating to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets. Under the terms of the agreement, EpiTherapeutics receives an up-front payment and wi…
therapeutic | 15 February 2011
